BayBridge Capital Group’s Pfizer PFE Stock Holding History

BayBridge Capital Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,188	Closed	-$229K	–	106
2026 Q1	$229K	Hold	9,188	–	–	0.14%	91
2025 Q4	$229K	Sell	9,188 -340	-4%	-$8.57K	0.14%	91
2025 Q3	$243K	Sell	9,528 -46,186	-83%	-$1.14M	0.15%	88
2025 Q2	$1.35M	Buy	55,714 +2,564	+5%	+$59.8K	0.87%	41
2025 Q1	$1.35M	Buy	53,150 +13,821	+35%	+$362K	0.97%	41
2024 Q4	$1.04M	Buy	39,329 +768	+2%	+$20.8K	0.76%	39
2024 Q3	$1.12M	Buy	+38,561	New	+$1.12M	0.8%	42

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BayBridge Capital Group's PFE Position: Q2 2026 in Review

BayBridge Capital Group sold out of Pfizer (PFE) in Q2 2026, closing a stake of 9,188 shares — an estimated $229K sold.

BayBridge Capital Group first reported a position in PFE in Q3 2024 and held it in 7 quarters. The position peaked at $1.35M in Q2 2025. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

BayBridge Capital Group reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
BayBridge Capital Group sold 9,188 Pfizer shares in Q2 2026, an estimated $229K.
BayBridge Capital Group first reported a position in Pfizer in Q3 2024 and held it in 7 quarters.
BayBridge Capital Group's Pfizer position peaked at $1.35M in Q2 2025.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on BayBridge Capital Group's 13F filing for Q2 2026, filed 14 Jul 2026.